Equities

Cell Source Inc

CLCS:QBB

Cell Source Inc

Actions
  • Price (USD)0.5132
  • Today's Change-0.05 / -8.87%
  • Shares traded21.88k
  • 1 Year change+2.64%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

  • Revenue in USD (TTM)0.00
  • Net income in USD-6.57m
  • Incorporated2012
  • Employees--
  • Location
    Cell Source Inc57 West 57Th Street, Suite 400NEW YORK 10019United StatesUSA
  • Phone+1 (646) 612-7554
  • Fax+1 (646) 612-7545
  • Websitehttps://cell-source.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Spruce Biosciences Inc7.10m-39.43m20.28m22.00--0.3927--2.86-0.9598-0.95980.17281.250.0798----244,862.10-44.28-41.24-55.51-46.49-----555.23-1,774.39---121.120.0399-------3.77------
GlycoMimetics Inc10.00k-39.74m20.63m35.00--1.81--2,063.49-0.6165-0.61650.00020.17640.0003--0.0836285.71-115.34-43.60-136.58-47.82-----397,350.50-2,243.52----0.00---86.67--20.97---29.82--
Pieris Pharmaceuticals Inc1.35m-15.95m21.04m46.00--1.29--15.56-12.61-12.611.0612.320.0338--1.9129,391.30-39.93-28.41-68.21-39.69-----1,179.96-94.61----0.00--65.288.0326.25---36.82--
Acurx Pharmaceuticals Inc0.00-16.44m21.12m4.00--8.18-----1.09-1.090.000.15890.00----0.00-250.15---498.16--------------0.00-------20.55------
Bolt Biotherapeutics Inc9.78m-65.09m21.69m100.00--0.3012--2.22-1.71-1.710.25671.880.0687----97,790.00-45.72-48.32-52.52-54.03-----665.56-2,267.00----0.00--37.48--21.45---6.61--
Cocrystal Pharma Inc0.00-18.70m21.87m12.00--1.72-----1.84-1.840.001.250.00----0.00-76.57-50.94-83.17-52.77-------1,501.78----0.00------53.69--33.34--
Aeon Biopharma Inc0.00-350.57m22.09m5.00---------9.61-9.610.00-0.81060.00----0.00-3,242.54----------------2.94---------631.85------
Cell Source Inc0.00-6.57m22.31m-----------0.1613-0.16130.00-0.43790.00-------2,039.39-1,758.85---------------3.74---------3.55------
Pulmatrix Inc10.01m-9.66m22.32m22.00--2.04--2.23-2.64-2.642.742.990.4145--23.16454,772.70-40.00-46.91-44.64-58.12-----96.51-238.04----0.00--20.21116.6225.03--104.29--
Ibio Inc175.00k-14.36m22.39m16.00--1.19--127.93-3.97-6.650.03072.060.0056----10,937.50-46.17-27.69-75.53-33.13-----8,204.57-1,862.11----0.0736-----35.5247.31---26.66--
Tempest Therapeutics Inc0.00-35.52m22.53m17.00--2.07-----1.57-1.570.000.43130.00----0.00-122.85-57.10-195.00-71.20------------0.426------17.41--36.40--
Forte Biosciences Inc0.00-34.20m22.84m11.00--2.44-----20.00-20.000.006.420.00----0.00-103.90-72.06-137.40-82.27-------491,850.00----0.00-------126.79---46.29--
Cadrenal Therapeutics Inc0.00-7.61m23.24m4.00--5.07-----7.05-7.050.002.760.00----0.00-108.76---125.13--------------0.00-------24.47------
Exicure Inc500.00k-4.01m23.59m6.00--15.27--47.18-2.26-2.260.2820.71120.0424--0.485283,333.34-33.98-41.52-45.26-55.78-----801.40-290.95----0.00---100.00---555.07------
Lisata Therapeutics Inc0.00-20.74m23.66m25.00--0.7023-----2.51-2.510.004.050.00----0.00-43.08-45.97-47.69-50.47------------0.00------61.57------
Data as of Nov 21 2024. Currency figures normalised to Cell Source Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.